Nervo Alice, Gallo Marco, Samà Maria Teresa, Felicetti Francesco, Alfano Martina, Migliore Enrica, Marchisio Filippo, Berardelli Rita, Arvat Emanuela, Piovesan Alessandro
Oncological Endocrinology Unit, Department of Medical Sciences, Città della Salute e della Scienza Hospital, Turin, Italy
Oncological Endocrinology Unit, Department of Medical Sciences, Città della Salute e della Scienza Hospital, Turin, Italy.
Anticancer Res. 2018 Mar;38(3):1643-1649. doi: 10.21873/anticanres.12396.
We retrospectively analyzed the efficacy and safety of lenvatinib in 12 patients with advanced radioiodine-refractory thyroid cancer in the setting of daily clinical practice.
The starting daily dose of lenvatinib was 24 mg, tapered in the case of adverse events. Disease status was periodically evaluated by a single radiologist and safety assessment was regularly performed.
After a median follow-up of 13.3 months, 6- and 12-month progression-free survival rates were 63.6% and 54.6%, respectively. Overall survival at 6 and 12 months was 83.3% and 75.0%. Partial response was observed in five patients, while two showed stable disease as their best response. Conversely, progressive disease at first radiological assessment was detected in four patients. All patients experienced at least one adverse event, including systemic and gastrointestinal toxicity, high blood pressure and hand-foot syndrome. In order to manage toxicity, transient drug interruption and dose reduction were required in 10 and 9 cases, respectively.
Our data confirm lenvatinib efficacy in patients with advanced thyroid cancer, despite an important toxic profile.
我们回顾性分析了在日常临床实践中，乐伐替尼对12例晚期放射性碘难治性甲状腺癌患者的疗效和安全性。
乐伐替尼的起始日剂量为24mg，若出现不良事件则逐渐减量。由一名放射科医生定期评估疾病状态，并定期进行安全性评估。
中位随访13.3个月后，6个月和12个月的无进展生存率分别为63.6%和54.6%。6个月和12个月的总生存率分别为83.3%和75.0%。5例患者出现部分缓解，2例患者最佳反应为病情稳定。相反，4例患者在首次影像学评估时出现疾病进展。所有患者均至少经历了一次不良事件，包括全身和胃肠道毒性、高血压和手足综合征。为了控制毒性，分别有10例和9例患者需要暂时中断用药和减少剂量。
我们的数据证实了乐伐替尼对晚期甲状腺癌患者的疗效，尽管其毒性反应较为明显。
